Two-dimensional coordination risedronate-manganese nanobelts as adjuvant for cancer radiotherapy and immunotherapy

Zhusheng Huang, Shiqian Huang, Simin Song, Yankui Ding, Hao Zhou, Shaoyin Zhang, Lixing Weng, Ying Zhang, Yiqiao Hu, Ahu Yuan, Yunlu Dai (), Zhimin Luo () and Lianhui Wang ()
Additional contact information
Zhusheng Huang: Nanjing University of Posts and Telecommunications
Shiqian Huang: Nanjing University of Posts and Telecommunications
Simin Song: Nanjing University of Posts and Telecommunications
Yankui Ding: Nanjing University of Posts and Telecommunications
Hao Zhou: Nanjing University of Posts and Telecommunications
Shaoyin Zhang: Nanjing University of Posts and Telecommunications
Lixing Weng: Nanjing University of Posts and Telecommunications
Ying Zhang: Nanjing University of Posts and Telecommunications
Yiqiao Hu: Nanjing University
Ahu Yuan: Nanjing University
Yunlu Dai: University of Macau
Zhimin Luo: Nanjing University of Posts and Telecommunications
Lianhui Wang: Nanjing University of Posts and Telecommunications

Nature Communications, 2024, vol. 15, issue 1, 1-20

Abstract: Abstract The irradiated tumor itself represents an opportunity to establish endogenous in situ vaccines. However, such in situ cancer vaccination (ISCV) triggered by radiation therapy (RT) alone is very weak and hardly elicits systemic anticancer immunity. In this study, we develop two-dimensional risedronate-manganese nanobelts (RMn-NBs) as an adjuvant for RT to address this issue. RMn-NBs exhibit good T2 magnetic resonance imaging performance and enhanced Fenton-like catalytic activity, which induces immunogenic cell death. RMn-NBs can inhibit the HIF-1α/VEGF axis to empower RT and synchronously activate the cGAS/STING pathway for promoting the secretion of type I interferon, thereby boosting RT-triggered ISCV and immune checkpoint blockade therapy against primary and metastatic tumors. RMn-NBs as a nano-adjuvant for RT show good biocompatibility and therapeutic efficacy, presenting a promising prospect for cancer radiotherapy and immunotherapy.

Date: 2024
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-024-53084-w Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:15:y:2024:i:1:d:10.1038_s41467-024-53084-w

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-024-53084-w

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().